Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer.

[1]  L. Sehn,et al.  Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. , 2022, The Lancet. Oncology.

[2]  A. Krishnan,et al.  Teclistamab in Relapsed or Refractory Multiple Myeloma. , 2022, The New England journal of medicine.

[3]  R. Sullivan,et al.  Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. , 2021, The New England journal of medicine.

[4]  N. Agarwal,et al.  Recent Advances in the Management of Metastatic Prostate Cancer. , 2021, JCO oncology practice.

[5]  Chan Hyuk Kim,et al.  A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand , 2021, Science Advances.

[6]  Jason T Giurleo,et al.  Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning , 2021, Scientific Reports.

[7]  J. Bono,et al.  Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC). , 2021 .

[8]  G. Morgan,et al.  Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. , 2021, Blood advances.

[9]  L. Fong,et al.  How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer , 2021, Prostate Cancer and Prostatic Diseases.

[10]  G. Salles,et al.  Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Salih,et al.  Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives , 2021, Cancers.

[12]  S. Balu-Iyer,et al.  Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins , 2021, BioDrugs.

[13]  P. Bogner,et al.  The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer , 2021, Clinical Cancer Research.

[14]  A. Buck,et al.  Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. , 2020, Immunotherapy.

[15]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[16]  C. Drake,et al.  Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Carles,et al.  Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[18]  Ye Chen,et al.  Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients , 2019, Journal of Cancer.

[19]  D. Xuan,et al.  A Modeling Framework to Characterize Cytokine Release upon T‐Cell–Engaging Bispecific Antibody Treatment: Methodology and Opportunities , 2019, Clinical and translational science.

[20]  A. Fielding,et al.  Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies , 2018, Human vaccines & immunotherapeutics.

[21]  S. Hitier,et al.  Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry , 2018, Journal of global oncology.

[22]  E. Crawford,et al.  Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations , 2018, Prostate Cancer and Prostatic Diseases.

[23]  P. Ott,et al.  Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  V. Velculescu,et al.  Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer , 2018, Oncotarget.

[25]  F. Saad,et al.  Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Blankenship,et al.  MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer , 2016, Molecular Cancer Therapeutics.

[27]  S. Pignata,et al.  Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival , 2016, Front. Pharmacol..

[28]  R. Kischel,et al.  Harnessing T cells to fight cancer with BiTE® antibody constructs – past developments and future directions , 2016, Immunological reviews.

[29]  S. Duensing,et al.  Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer , 2015, Modern Pathology.

[30]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[31]  H. Scher,et al.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Andreas Wolf,et al.  Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. , 2012, Blood.

[33]  M Laird Forrest,et al.  Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development. , 2011, Therapeutic delivery.

[34]  S. Landas,et al.  Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues , 2006, World Journal of Surgery.

[35]  Prabhjot Kaur,et al.  Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.